ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer

Abstract Bruton's tyrosine kinase (BTK) plays a central and pivotal role in controlling the pathways involved in the pathobiology of cancer, rheumatoid arthritis (RA), and other autoimmune disorders. ZYBT1 is a potent, irreversible, specific BTK inhibitor that inhibits the ibrutinib‐resistant C481S...

Descrición completa

Detalles Bibliográficos

Principais autores:	Krishnarup Ghoshdastidar, Hoshang Patel, Hitesh Bhayani, Ankit Patel, Kinjal Thakkar, Dinesh Patel, Manoranjan Sharma, Jaideep Singh, Jogeswar Mohapatra, Abhijit Chatterjee, Dipam Patel, Rajesh Bahekar, Rajiv Sharma, Lakshmikant Gupta, Nirmal Patel, Poonam Giri, Nuggehally R. Srinivas, Mukul Jain, Debdutta Bandyopadhyay, Pankaj R. Patel, Ranjit C. Desai
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2020-08-01
Series:	Pharmacology Research & Perspectives
Assuntos:	Bruton's tyrosine kinase cancer irreversible inhibitor rheumatoid arthritis xenograft
Acceso en liña:	https://doi.org/10.1002/prp2.565
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!